Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Current Deferred Revenue (2019 - 2020)

aTYR PHARMA's Current Deferred Revenue history spans 2 years, with the latest figure at $53000.0 for Q3 2020.

  • For Q3 2020, Current Deferred Revenue fell 84.94% year-over-year to $53000.0; the TTM value through Sep 2020 reached $53000.0, down 84.94%, while the annual FY2019 figure was $208000.0, N/A changed from the prior year.
  • Current Deferred Revenue reached $53000.0 in Q3 2020 per ATYR's latest filing, down from $201000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $630000.0 in Q1 2019 to a low of $53000.0 in Q3 2020.